Market Report Source

Overview

Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.

Scope of this report:

• Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017
• Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate
• Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
• Quantification of the market size of the cytotoxic therapy cancer brands in the seven major pharmaceutical markets with the rest of world markets

Research and analysis highlights:

The cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.

As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.

Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.

Key reasons to read this report:

• Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2007 to 2017
• Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
• Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

Table of Contents

ABOUT DATAMONITOR HEALTHCARE 2
About the Oncology pharmaceutical analysis team 2

CHAPTER 1 EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the cytotoxic therapy cancer brands market 4
Related reports 5
Upcoming reports 5

CHAPTER 2 MARKET DEFINITION 8
Cytotoxic therapies by ATC class 9
L1A – Alkylating agents 9
L1B – Antimetabolites 9
L1C – Vinca alkaloids and other plant-derived products 9
L1D – Antineoplastic antibiotics 10
L1X2 – Platinum compounds 10
Report classification of cytotoxic therapies 10
Antimetabolites 10
Mitotic inhibitors 11
DNA-interactive agents 11
Topoisomerase poisons 11
Non-covalent DNA binding drugs 12
Covalent DNA binding drugs – alkylating agents 12

CHAPTER 3 MARKET OVERVIEW AND FORECASTS 13
Seven major markets13
Current market assessment 13
Sales by class 13
Sales by brand 14
Sales by country 18
Future market assessment 21
Sales by class 21
Sales by brand 24
Sales by country 31

US 34
Current market assessment 34
Sales by class 34
Sales by brand 36
Future market assessment 37
Sales by class 37
Sales by brand 40

Japan 43
Current market assessment 43
Sales by class 43
Sales by brand 45
Future market assessment 46
Sales by class 46
Sales by brand 49

5EU 53
Current market assessment 53
Sales by class 53
Sales by brand 55
Future market assessment 56
Sales by class 56
Sales by brand 59

France 63
Current market assessment 63
Sales by class 63
Sales by brand 65
Future market assessment 66
Sales by class 66
Sales by brand 69

Germany 73
Current market assessment 73
Sales by class 73
Sales by brand 75
Future market assessment 76
Sales by class 76
Sales by brand 79

Italy 83
Current market assessment 83
Sales by class 83
Sales by brand 85
Future market assessment 86
Sales by class 86
Sales by brand 89

Spain 93
Current market assessment 93
Sales by class 93
Sales by brand 95
Future market assessment 96
Sales by class 96
Sales by brand 99

UK 103
Current market assessment 103
Sales by class 103
Sales by brand 105
Future market assessment 106
Sales by class 106
Sales by brand 109

Rest of World snapshot 113
Current market assessment 113
Global cytotoxics market 113
Global antimetabolites market 115
Global mitotic inhibitors market 117
Global DNA-interactive agents market 119

CHAPTER 4 MARKET DYNAMICS 121
Brand analysis by class 121
Mitotic inhibitor brands are the smallest class, representing 16% cytotoxic therapies 121
Brand analysis by indication 122
Taxotere and TS-1 are the leading cytotoxic therapy cancer brands in terms of number of approved indications 122
Breast cancer is the indication with the most approved cytotoxic therapy cancer brands 127
Brand analysis by company 129
Sanofi-Aventis has the highest number of cytotoxic therapy cancer brands, although patent expiries are looming 129
Sanofi-Aventis 131
Taiho 131
Johnson & Johnson 131
Brand analysis by event 132
Abraxane will experience the greatest number of forecast events across the seven major markets 132
Brand analysis by sales growth 134
All cytotoxic drug classes show positive sales growth to 2017 134
Sales growth of antimetabolite brands 136
Sales growth of DNA-interactive agent brands 138
Sales growth of mitotic inhibitor brands 140
Brand versus generic market snapshot 142
Seven major markets 142
Generics – higher volume, lower value; Brands – lower volume, higher value 142
US 143
Japan 144
5EU 145
France 146
Germany 147
Italy 148
Spain 149
UK 150

CHAPTER 5 BRAND PROFILES AND FORECASTS 151

Abraxane 151
Brand profile 151
Brand forecast events 153
Brand forecast to 2017 154
Next generation taxane set to enter the EU markets 154

Alimta 156
Brand profile 156
Brand forecast events 157
Brand forecast to 2017 158
Line extensions and horizontal expansion will boost Alimta’s sales over the forecast period 158

Arranon 160
Brand profile 160
Brand forecast events 161
Brand forecast to 2017 162

Calsed 163
Brand profile 163
Brand forecast events 164
Brand forecast to 2017 165

Camptosar 166
Brand profile 166
Brand forecast events 167
Brand forecast to 2017 168
Increased generic competition decreases sales across the seven major markets 168

Clolar/Evoltra 169
Brand profile 169
Brand forecast events 170
Brand forecast to 2017 171

Dacogen 172
Brand profile 172
Brand forecast events 173
Brand forecast to 2017 174
Anticipated high uptake set to make Dacogen a leading cytotoxic therapy cancer brand 174

Doxil 176
Brand profile 176
Brand forecast events 177
Brand forecast to 2017 178

Ellence 179
Brand profile 179
Brand forecast events 180
Brand forecast to 2017 180

Eloxatin 181
Brand profile 181
Brand forecast events 182
Brand forecast to 201 183
Top-seller likely to face strong generic competition 183

Furtulon 185
Brand profile 185
Brand forecast events 186
Brand forecast to 2017 186

Gemzar 187
Brand profile 187
Brand forecast events 188
Brand forecast to 2017 189
Blockbuster sales set to be dented by generic entry 189

Gliadel 191
Brand profile 191
Brand forecast events 192
Brand forecast to 2017 193

Hycamtin 194
Brand profile 194
Brand forecast events 195
Brand forecast to 2017 196

Ixempra 197
Brand profile 197
Brand forecast events 198
Brand forecast to 2017 199
Launch in big indication presents opportunity for novel mitotic inhibitor 199

Taxol 200
Brand profile 200
Brand forecast events 201
Brand forecast to 2017 201

Taxotere 202
Brand profile 202
Brand forecast events 203
Brand forecast to 2017 204
Approval in new indications and extensive use in major tumor types means blockbuster status will be maintained 204

Temodar 206
Brand profile 206
Brand forecast events 207
Brand forecast to 2017 208

Tomudex 209
Brand profile 209
Brand forecast events 210
Brand forecast to 2017 210

Treanda 211
Brand profile 211
Brand forecast events 212
Brand forecast to 2017 213

TS-1 214
Brand profile 214
Brand forecast events 215
Brand forecast to 2017 216

UFT 217
Brand profile 217
Brand forecast events 218
Brand forecast to 2017 218

Vidaza 219
Brand profile 219
Brand forecast events 220
Brand forecast to 2017 221
Entry into new markets will help boost sales to blockbuster status 221

Xeloda 223
Brand profile 223
Brand forecast events 224
Brand forecast to 2017 225
New indications and line extensions will ensure increasing sales 225

Yondelis 226
Brand profile 226
Brand forecast events 227
Brand forecast to 2017 228

APPENDIX A – MARKET ASSUMPTIONS 229
Country-specific assumptions and events 229

• Effect of Medicare Modernization Act in the US 229
• Biennial price cuts in Japan 229
• Generic erosion assumptions 229

Data definitions, limitations and assumptions 230

• Standard units 230
• Japanese market data 230
• Derivation of sales forecasts and pricing trends 230

Forecasts 231
Forecast methodology 231

APPENDIX B 232
Bibliography 232

• Journals 232
• Websites 232

List of figures 237
Abbreviations 238
Report methodology 239

• About Datamonitor 239
• About Datamonitor Healthcare 239

Disclaimer 241

List of Tables
Table 1: Definition of the cancer market by ATC class, 2008 8

Table 2: Seven major market sales of cytotoxic therapy cancer brands by drug class, 2007 13

Table 3: Seven major market sales of cytotoxic therapy cancer brands, 2007 15

Table 4: Individual country sales and market share of cytotoxic therapy cancer brands in the seven major markets, 2007 19

Table 5: Seven major market forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 21

Table 6: Seven major market forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 24

Table 7: Individual country forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 31

Table 8: US sales of cytotoxic therapy cancer brands by drug class, 2007 34

Table 9: US sales of cytotoxic therapy cancer brands, 2007 36

Table 10: US forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 37

Table 11: US forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 40

Table 12: Japan sales of cytotoxic therapy cancer brands by drug class, 2007 44

Table 13: Japan sales of cytotoxic therapy cancer brands, 2007 45

Table 14: Japan forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 46

Table 15: Japan sales of cytotoxic therapy cancer brands ($m), 2007-2017 49

Table 16: 5EU sales of cytotoxic therapy cancer brands by drug class, 2007 53

Table 17: 5EU major market sales of cytotoxic therapy cancer brands, 2007 55

Table 18: 5EU forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 56

Table 19: 5EU forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 59

Table 20: France sales of cytotoxic therapy cancer brands by drug class, 2007 63

Table 21: France sales of cytotoxic therapy cancer brands, 2007 65

Table 22: France forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 66

Table 23: France sales of cytotoxic therapy cancer brands ($m), 2007-2017 69

Table 24: Germany sales of cytotoxic therapy cancer brands by drug class, 2007 73

Table 25: Germany sales of cytotoxic therapy cancer brands, 2007 75

Table 26: Germany forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 76

Table 27: Germany forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 79

Table 28: Italy sales of cytotoxic therapy cancer brands by drug class, 2007 83

Table 29: Italy sales of cytotoxic therapy cancer brands, 2007 85

Table 30: Italy forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 86

Table 31: Italy forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 89

Table 32: Spain sales of cytotoxic therapy cancer brands by drug class, 2007 93

Table 33: Spain sales of cytotoxic therapy cancer brands, 2007 95

Table 34: Spain forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 96

Table 35: Spain forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 99

Table 36: UK sales of cytotoxic therapy cancer brands by drug class, 2007 103

Table 37: UK sales of cytotoxic therapy cancer brands, 2007 105

Table 38: UK forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 106

Table 39: UK forecast sales of cytotoxic therapy cancer brands ($m), 2007-2017 109

Table 40: US, Japan, 5EU and RoW total cytotoxic therapy market sales, 2007 113

Table 41: US, Japan, 5EU and RoW total antimetabolite therapy market sales, 2007 115

Table 42: US, Japan, 5EU and RoW total mitotic inhibitor therapy market sales, 2007 117

Table 43: US, Japan, 5EU and RoW total DNA-interactive therapy market sales, 2007 119

Table 44: Approved oncology indications for antimetabolite cytotoxic therapy cancer brands in US, 5EU and Japan, 2008 125

Table 45: Approved oncology indications for mitotic inhibitor cytotoxic therapy cancer brands in US, 5EU and Japan, 2008 126

Table 46: Approved oncology indications for DNA-interactive cytotoxic therapy cancer brands in US, 5EU and Japan, 2008 127

Table 47: CAGR (%) of cytotoxic therapy cancer brands by drug class in the seven major markets, 2007-2017 134

Table 48: CAGR (%) of antimetabolite cytotoxic therapy cancer brands in the seven major markets, 2007-2017 136

Table 49: CAGR (%) of DNA-interactive cytotoxic therapy cancer brands in the seven major markets, 2007-2017 138

Table 50: CAGR (%) of mitotic inhibitor cytotoxic therapy cancer brands in the seven major markets, 2007-2017 140

Table 51: Abraxane: key facts 152

Table 52: Abraxane: brand forecast events 153

Table 53: Abraxane forecast sales in the seven major markets ($m), 2007-2017 154

Table 54: Alimta: key facts 156

Table 55: Alimta: brand forecast events 157

Table 56: Alimta forecast sales in the seven major markets ($m), 2007-2017 158

Table 57: Arranon: key facts 160

Table 58: Arranon: brand forecast events 161

Table 59: Arranon forecast sales in the seven major markets ($m), 2007-2017 162

Table 60: Calsed: key facts 163

Table 61: Calsed: brand forecast events 164

Table 62: Calsed forecast sales in the seven major markets ($m), 2007-2017 165

Table 63: Camptosar: key facts 166

Table 64: Camptosar: brand forecast events 167

Table 65: Camptosar forecast sales in the seven major markets ($m), 2007-2017 168

Table 66: Clolar/ Evoltra: key facts 169

Table 67: Clolar/ Evoltra: brand forecast events 170

Table 68: Clolar/Evoltra forecast sales in the seven major markets ($m), 2007-2017 171

Table 69: Dacogen: key facts 172

Table 70: Dacogen: brand forecast events 173

Table 71: Dacogen forecast sales in the seven major markets ($m), 2007-2017 174

Table 72: Doxil: key facts 176

Table 73: Doxil: brand forecast events 177

Table 74: Doxil forecast sales in the seven major markets ($m), 2007-2017 178

Table 75: Ellence: key facts 179

Table 76: Ellence forecast sales in the seven major markets ($m), 2007-2017 180

Table 77: Eloxatin: key facts 181

Table 78: Eloxatin: brand forecast events 182

Table 79: Eloxatin forecast sales in the seven major markets ($m), 2007-2017 183

Table 80: Furtulon: key facts 185

Table 81: Furtulon forecast sales in the seven major markets ($m), 2007-2017 186

Table 82: Gemzar: key facts 187

Table 83: Gemzar: brand forecast events 188

Table 84: Gemzar forecast sales in the seven major markets ($m), 2007-2017 189

Table 85: Gliadel: key facts 191

Table 86: Gliadel: brand forecast events 192

Table 87: Gliadel forecast sales in the seven major markets ($m), 2007-2017 193

Table 88: Hycamtin: key facts 194

Table 89: Hycamtin: brand forecast events 195

Table 90: Hycamtin forecast sales in the seven major markets ($m), 2007-2017 196

Table 91: Ixempra: key facts 197

Table 92: Ixempra: brand forecast events 198

Table 93: Ixempra forecast sales in the seven major markets ($m), 2007-2017 199

Table 94: Taxol: key facts 200

Table 95: Taxol forecast sales in the seven major markets ($m), 2007-2017 201

Table 96: Taxotere: key facts 202

Table 97: Taxotere: brand forecast events 203

Table 98: Taxotere forecast sales in the seven major markets ($m), 2007-2017 204

Table 99: Temodar: key facts 206

Table 100: Temodar: brand forecast events 207

Table 101: Temodar forecast sales in the seven major markets ($m), 2007-2017 208

Table 102: Tomudex: key facts 209

Table 103: Tomudex forecast sales in the seven major markets ($m), 2007-2017 210

Table 104: Treanda: key facts 211

Table 105: Treanda: brand forecast events 212

Table 106: Treanda forecast sales in the seven major markets ($m), 2007-2017 213

Table 107: TS-1: key facts 214

Table 108: TS-1: brand forecast events 215

Table 109: TS-1 forecast sales in the seven major markets ($m), 2007-2017 216

Table 110: UFT: key facts 217

Table 111: UFT forecast sales in the seven major markets ($m), 2007-2017 218

Table 112: Vidaza: key facts 219

Table 113: Vidaza: brand forecast events 220

Table 114: Vidaza forecast sales in the seven major markets ($m), 2007-2017 221

Table 115: Xeloda: key facts 223

Table 116: Xeloda: brand forecast events 224

Table 117: Xeloda forecast sales in the seven major markets ($m), 2007-2017 225

Table 118: Yondelis: key facts 226

Table 119: Yondelis: brand forecast events 227

Table 120: Yondelis forecast sales in the seven major markets ($m), 2007-2017 228

Table 121: Abbreviations used in Commercial Insight: Cytotoxic Therapy Cancer Brands 238

List of Figures
Figure 1: Seven major market sales and market share of cytotoxic therapy cancer brands by drug class, 2007 14

Figure 2: Seven major market sales and market share of antimetabolite cytotoxic therapy cancer brands, 2007 16

Figure 3: Seven major market sales and market share of mitotic inhibitor cytotoxic therapy cancer brands, 2007 17

Figure 4: Seven major market sales and market share of DNA-interactive cytotoxic therapy cancer brands, 2007 18

Figure 5: Individual country sales and market share of cytotoxic therapy cancer brands in the seven major markets,, 2007 20

Figure 6: Seven major market forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 22

Figure 7: Seven major market forecast sales and market share of cytotoxic therapy cancer brands by drug class, 2017 23

Figure 8: Seven major market forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 25

Figure 9: Seven major market forecast sales and market share of antimetabolite cytotoxic therapy cancer brands, 2017 26

Figure 10: Seven major market forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 27

Figure 11: Seven major market forecast sales and market share of mitotic inhibitor cytotoxic therapy cancer brands, 2017 28

Figure 12: Seven major market forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 29

Figure 13: Seven major market forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2017 30

Figure 14: Individual country forecast sales of cytotoxic therapy cancer brands, 2007-2017 32

Figure 15: Individual country forecast sales and market share of cytotoxic therapy cancer brands, 2017 33

Figure 16: US sales and market share of cytotoxic therapy cancer brands by drug class, 2007 35

Figure 17: US forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 38

Figure 18: US forecast sales and market share of cytotoxic therapy cancer brands by drug class, 2017 39

Figure 19: US forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 41

Figure 20: US forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 42

Figure 21: US forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 43

Figure 22: Japan sales and market share of cytotoxic therapy cancer brands by drug class, 2007 44

Figure 23: Japan forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 47

Figure 24: Japan sales and market share of cytotoxic therapy cancer brands by drug class, 2017 48

Figure 25: Japan forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 50

Figure 26: Japan forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 51

Figure 27: Japan forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 52

Figure 28: 5EU sales and market share of cytotoxic therapy cancer brands by drug class, 2007 54

Figure 29: 5EU forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 57

Figure 30: 5EU forecast sales and market share of cytotoxic therapy cancer brands by drug class, 2017 58

Figure 31: 5EU forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 60

Figure 32: 5EU forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 61

Figure 33: 5EU forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 62

Figure 34: France sales and market share of cytotoxic therapy cancer brands by drug class, 2007 64

Figure 35: France forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 67

Figure 36: France forecast sales of cytotoxic therapy cancer brands by drug class, 2017 68

Figure 37: France forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 70

Figure 38: France forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 71

Figure 39: France forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 72

Figure 40: Germany sales and market share of cytotoxic therapy cancer brands by drug class, 2007 74

Figure 41: Germany forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 77

Figure 42: Germany forecast sales and market share of cytotoxic therapy cancer brands by drug class, 2017 78

Figure 43: Germany forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 80

Figure 44: Germany forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 81

Figure 45: Germany forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 82

Figure 46: Italy sales and market share of cytotoxic therapy cancer brands by drug class, 2007 84

Figure 47: Italy forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 87

Figure 48: Italy forecast sales of cytotoxic therapy cancer brands by drug class, 2017 88

Figure 49: France forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 90

Figure 50: Italy forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 91

Figure 51: Italy forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 92

Figure 52: Spain sales and market share of cytotoxic therapy cancer brands by drug class, 2007 94

Figure 53: Spain forecast sales of cytotoxic therapy cancer brands by drug class ($m), 2007-2017 97

Figure 54: Spain forecast sales of cytotoxic therapy cancer brands by drug class, 2017 98

Figure 55: Spain forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 100

Figure 56: Spain forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 101

Figure 57: Spain forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 102

Figure 58: UK sales and market share of cytotoxic therapy cancer brands by drug class, 2007 104

Figure 59: UK forecast sales of cytotoxic therapy cancer brands by drug class, 2007-2017 107

Figure 60: UK forecast sales and market share of cytotoxic therapy cancer brands by drug class, 2017 108

Figure 61: UK forecast sales of antimetabolite cytotoxic therapy cancer brands, 2007-2017 110

Figure 62: UK forecast sales of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 111

Figure 63: UK forecast sales of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 112

Figure 64: US, Japan, 5EU and RoW total cytotoxic therapy market sales and market share, 2007 114

Figure 65: US, Japan, 5EU and RoW total antimetabolite therapy market sales and market share, 2007 116

Figure 66: US, Japan, 5EU and RoW total mitotic inhibitor therapy market sales and market share, 2007 118

Figure 67: US, Japan, 5EU and RoW total DNA-interactive therapy market sales and market share, 2007 120

Figure 68: Number of approved cytotoxic therapy cancer brands by drug class, 2007 121

Figure 69: Analysis of cytotoxic therapy cancer brands by number of approved oncology indications in the seven major markets, 2008 123

Figure 70: Analysis of oncology indications by number of approved cytotoxic therapy cancer brands in the seven major markets, 2008 128

Figure 71: Analysis of companies by number of approved cytotoxic therapy cancer brands in the seven major markets 130

Figure 72: Analysis of cytotoxic therapy cancer brands by number of forecast events, 2008-2017 133

Figure 73: CAGR (%) of cytotoxic therapy cancer brands by drug class in the seven major markets, 2007-2017 135

Figure 74: CAGR (%) of antimetabolite cytotoxic therapy cancer brands, 2007-2017 137

Figure 75: CAGR (%) of DNA-interactive cytotoxic therapy cancer brands, 2007-2017 139

Figure 76: CAGR (%) of mitotic inhibitor cytotoxic therapy cancer brands, 2007-2017 141

Figure 77: Seven major market branded and generic cytotoxic therapy volume and value sales by drug class, 2007 142

Figure 78: US branded and generic cytotoxic therapy volume and value sales by drug class, 2007 143

Figure 79: Japan branded and generic cytotoxic therapy volume and value sales by drug class, 2007 144

Figure 80: 5EU branded and generic cytotoxic therapy volume and value sales by drug class, 2007 145

Figure 81: France branded and generic cytotoxic therapy volume and value sales by drug class, 2007 146

Figure 82: Germany branded and generic cytotoxic therapy volume and value sales by drug class, 2007 147

Figure 83: Italy branded and generic cytotoxic therapy volume and value sales by drug class, 2007 148

Figure 84: Spain branded and generic cytotoxic therapy volume and value sales by drug class, 2007 149

Figure 85: UK branded and generic cytotoxic therapy volume and value sales by drug class, 2007 150